Last Updated: May 10, 2026

Profile for Hungary Patent: S2000049


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Hungary Patent: S2000049

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
8,299,057 Mar 10, 2032 Genentech Inc ROZLYTREK entrectinib
8,673,893 Jul 8, 2028 Genentech Inc ROZLYTREK entrectinib
9,029,356 Jul 8, 2028 Genentech Inc ROZLYTREK entrectinib
9,085,558 Jul 8, 2028 Genentech Inc ROZLYTREK entrectinib
9,255,087 Jul 8, 2028 Genentech Inc ROZLYTREK entrectinib
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Comprehensive Analysis of the Scope, Claims, and Patent Landscape for Hungary Patent HUS2000049

Last updated: August 30, 2025


Introduction

Patent HUS2000049 relates to a pharmaceutical invention granted in Hungary, providing exclusive rights for specific drug compositions or methods. Analyzing its scope and claims is vital for understanding its commercial boundaries, potential overlaps with other patents, and its position within the broader patent landscape. This review systematically examines the patent's claims, their legal scope, and contextualizes these within the wider pharmaceutical patent cosmos.


Background and Patent Overview

Hungary's patent HUS2000049 was granted on [specific date], indicating a priority or application filing earlier (details pending based on publicly available databases). While the exact patent title and inventors are not provided here, patents of this nature typically focus on novel drug compounds, formulations, delivery mechanisms, or manufacturing processes.

The core purpose of such patents is to secure exclusive rights preventing unauthorized commercial use, thereby incentivizing innovation. The scope hinges on the accurate interpretation of claims, which define the legal boundaries of protection.


Scope of the Patent: Claims Analysis

1. Types of Claims

Patent HUS2000049 likely contains a series of claims divided into independent and dependent claims:

  • Independent claims: Broader, establishing the inventive core—e.g., a novel pharmaceutical composition, active ingredient combination, or delivery method.
  • Dependent claims: Narrower, elaborating particular embodiments, specific formulations, or optimized parameters.

2. Scope Definition and Interpretation

The scope's breadth depends on the language used within these claims:

  • Product claims: Often specify the chemical structure of active compounds, dosage forms, or combination therapy parameters. For example, if the claim covers a specific chemical compound, it excludes other variants unless explicitly stated.
  • Method claims: Encompass processes for manufacturing or administering the drug. They provide protection for specific procedural steps.
  • Use claims: Protect specific therapeutic applications or indications.

Example (hypothetical):
An independent claim might state: "A pharmaceutical composition comprising active compound X in a pharmaceutically acceptable carrier for the treatment of disease Y."
This claim covers any composition with compound X for disease Y, but not necessarily other uses or carriers unless specified.

3. Patent Claim Limitations

In Hungarian patent law, scope is constrained by the language of the claims and the Euro-PCT standards. The claims must be clear, concise, and supported by the description. Overly broad claims risk being invalidated if they encompass prior art beyond the inventive step, while overly narrow claims may limit commercial protection.

4. Notable Features of the Claims

  • Novelty and Inventive Step: The claims must delineate features that are new and non-obvious over prior art, which includes previous patents, scientific literature, or existing drugs.
  • Specificity Vs. Generality: The claims balance between being sufficiently specific to establish patentability and broad enough to prevent easy design-arounds.

Patent Landscape and Strategic Context

1. Global Patent Environment

Hungary is part of the European Patent Convention, allowing for filings via the European Patent Office (EPO). The patent landscape for pharmaceutical compounds is complex, with overlapping patents at the European and international levels.

  • Prior Art Searches: Critical to identify competing patents or patent applications with similar claims.
  • Filing Strategies: Many firms file a core patent in Hungary and extend protection through European or PCT applications to cover broader markets.

2. Competitor Patent Landscape

The patent landscape often features:

  • Blocking patents: Similar compounds or formulations that could impede commercialization.
  • Follow-up patents: Secondary patents related to improved formulations or delivery methods.
  • Publicly available applications: Patent applications published but not yet granted, representing potential future competition or litigation risks.

3. Patent Family and Priority

Understanding whether HUS2000049 is part of a broader patent family helps assess its scope:

  • National patent family: Sequence of related filings across jurisdictions.
  • Priority date: Establishes the earliest filing, impacting the novelty assessment.
  • Expiration timeline: Typically 20 years from filing, but can vary with extensions (e.g., supplementary protection certificates for pharmaceuticals).

4. Patent Valuation and Enforcement

In Hungary, patent enforcement mechanisms include civil and criminal proceedings. The scope directly influences the ability to enforce rights against infringers.

A well-defined, specific claim set enhances enforceability, while overly broad claims risk invalidation or difficulty in proving infringement.


Legal Status and Challenges

The patent’s enforceability depends on:

  • Validity: Whether the claims adhere to statutory requirements and are sufficiently supported by the description.
  • Potential opposition or nullity actions: Third parties may challenge the patent based on prior art or insufficient inventive step.
  • Infringement risk: Competitors may design-around claims, especially if claims are narrowly drafted.

Continuous monitoring of Hungarian and EPO patent registers is essential for maintaining awareness of potential challenges or litigation.


Conclusion and Strategic Implications

Patent HUS2000049’s scope primarily hinges on the language of its claims, which define the extent of exclusivity. Precise, well-defined claims support robust protection while minimizing invalidity risks. Its position within the patent landscape—considering prior art, competitor filings, and international patent strategies—determines its commercial strength.

Enterprises should:

  • Conduct detailed patent clearance searches to evaluate infringement risks.
  • Consider filing in other jurisdictions for broader coverage.
  • Monitor potential infringing activities and patent challenges.

Key Takeaways

  • Claims clarity is critical: Well-drafted claims ensure enforceability and prevent workarounds.
  • Scope balance: Broad claims offer extensive protection but are susceptible to invalidation; narrow claims provide tight protection but risk limited coverage.
  • Broader patent landscape: Cross-jurisdictional filings and prior art analysis are essential for strategic positioning.
  • Patent validity and enforcement: Regular patent status review and proactive enforcement strategies optimize market exclusivity.
  • Continued monitoring: Tracking competitors and patent challenges sustains competitive advantages.

FAQs

1. What determines the scope of the claims in patent HUS2000049?
The scope is defined by the specific language used within the independent and dependent claims, supported by the detailed description, and interpreted according to Hungarian patent law principles.

2. How does Hungary's patent law influence the protection of pharmaceutical inventions like HUS2000049?
Hungarian law requires claims to be clear, supported by description, novel, and involve an inventive step. The legal framework supports enforcement but enforces strict claim interpretation.

3. Can the claims of HUS2000049 be challenged or invalidated?
Yes, through opposition proceedings or nullity actions based on prior art, lack of inventive step, insufficient disclosure, or ambiguous claims.

4. How important is the patent landscape analysis when dealing with HUS2000049?
It is crucial to identify potential infringement risks, avoid patent infringement, and plan strategic filings to secure market exclusivity.

5. Is it advisable to extend protection beyond Hungary for this patent?
Yes. Filing through the EPO or PCT routes can extend protection to Europe and other jurisdictions, maximizing commercial coverage and reducing infringement risks.


References:

  1. Hungarian Patent Office (HPO). [Official Patent Database].
  2. European Patent Office (EPO). Patent Search and Examination Guidelines.
  3. World Intellectual Property Organization (WIPO). Patent Cooperation Treaty (PCT) resources.
  4. European Patent Convention (EPC). Patent Law Provisions.
  5. Recent legal opinions and patent analysis reports from industry experts.

Note: For an exhaustive and precise assessment, access to the full patent document, claims, legal status, and family details from official patent registers is recommended.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.